Bristol Myers Squibb to lay off 2,200 jobs under $1.5bn cost savings initiative
The “strategic productivity initiative” to be executed by the American pharmaceutical company will also involve reducing management layers,…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
26 Apr 24
The “strategic productivity initiative” to be executed by the American pharmaceutical company will also involve reducing management layers,…
26 Apr 24
The binding offer consists of an upfront cash payment of €190m and up to €85m in potential earnout…
26 Apr 24
The biotechnology firm will start its Phase 2a FREE001-TRD-201 clinical trial for FREE001, a ketamine-based combination therapy in…
25 Apr 24
The sBLA submission is supported by data from Part 1 of RUBY Phase 3 trial which successfully met…
25 Apr 24
The approval was based on results from three controlled clinical trials of females aged 18 and above in…
25 Apr 24
The approval was based on the results from the Phase 3 PROTECT study which reached its primary endpoint…
24 Apr 24
The deal includes EP262, a first-in-class, potent, highly selective, once-daily small molecule MRGPRX2 antagonist, and EP547, a first-in-class…
24 Apr 24
The approval was based on the results from the Phase 3 EMBARK trial which met its primary endpoint…
24 Apr 24
The approval is based on results from the ALPHA Phase 3 trial in which Voydeya met the primary…
24 Apr 24
The designation was requested based on the potential for MC-1 to address an unmet medical need for PNPO…